327 related articles for article (PubMed ID: 15304240)
21. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
[TBL] [Abstract][Full Text] [Related]
23. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoids differentially control synthesis of acetylcholinesterase and butyrylcholinesterase in rat liver and brain.
Weber U; Brank M; Grubic Z
Chem Biol Interact; 1999 May; 119-120():341-7. PubMed ID: 10421470
[TBL] [Abstract][Full Text] [Related]
25. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
26. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
27. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: effects of sex hormone withdrawal.
Alves-Amaral G; Pires-Oliveira M; Andrade-Lopes AL; Chiavegatti T; Godinho RO
Chem Biol Interact; 2010 Jun; 186(1):9-15. PubMed ID: 20399201
[TBL] [Abstract][Full Text] [Related]
28. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
Darvesh S; Hopkins DA
J Comp Neurol; 2003 Aug; 463(1):25-43. PubMed ID: 12811800
[TBL] [Abstract][Full Text] [Related]
29. Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity.
Wszelaki N; Kuciun A; Kiss AK
Acta Pharm; 2010 Mar; 60(1):119-28. PubMed ID: 20228046
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
[TBL] [Abstract][Full Text] [Related]
31. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of suberogorgin on acetylcholinesterase.
Peng WD; Xu SB; Peng X
Zhongguo Yao Li Xue Bao; 1996 Jul; 17(4):369-72. PubMed ID: 9812727
[TBL] [Abstract][Full Text] [Related]
33. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
Andrisano V; Naldi M; De Simone A; Bartolini M
Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
[TBL] [Abstract][Full Text] [Related]
34. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.
Markowicz-Piasecka M; Sikora J; Mateusiak Ł; Mikiciuk-Olasik E; Huttunen KM
Oxid Med Cell Longev; 2017; 2017():7303096. PubMed ID: 28770024
[TBL] [Abstract][Full Text] [Related]
35. Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles.
Samadi A; Marco-Contelles J; Soriano E; Alvarez-Pérez M; Chioua M; Romero A; González-Lafuente L; Gandía L; Roda JM; López MG; Villarroya M; García AG; Ríos Cde L
Bioorg Med Chem; 2010 Aug; 18(16):5861-72. PubMed ID: 20656495
[TBL] [Abstract][Full Text] [Related]
36. [Effects of cornel iridoid glycoside on activity of cholinesterases in vitro].
Chu SJ; Zhang L; Liu G; Zhou WX; Li L
Zhongguo Zhong Yao Za Zhi; 2013 May; 38(9):1331-4. PubMed ID: 23944063
[TBL] [Abstract][Full Text] [Related]
37. Inhibition and recovery of maternal and fetal cholinesterase enzymes following a single oral dose of chlorpyrifos in rats.
Ashry KM; Abu-Qare AW; Saleem FR; Hussein YA; Hamza SM; Kishk AM; Abou-Donia MB
Arch Toxicol; 2002 Feb; 76(1):30-9. PubMed ID: 11875622
[TBL] [Abstract][Full Text] [Related]
38. Ontogenetic differences in the regional and cellular acetylcholinesterase and butyrylcholinesterase activity in the rat brain.
Lassiter TL; Barone S; Padilla S
Brain Res Dev Brain Res; 1998 Jan; 105(1):109-23. PubMed ID: 9497085
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
40. Anticholinesterase and Antioxidant Activities of Natural Abietane Diterpenoids with Molecular Docking Studies.
Topçu G; Akdemir A; Kolak U; Öztürk M; Boğa M; Bahadori F; Çakmar SDH
Curr Alzheimer Res; 2020; 17(3):269-284. PubMed ID: 32329687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
